MedTrace Logo

A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate

NCT00904748 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2021-02-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to perform a relative bioavailability study between two formulations of sildenafil citrate.

Conditions

Interventions

DRUG

sildenafil citrate 100 mg CT

sildenafil citrate 100 mg CT, single dose without water

DRUG

sildenafil citrate 100 mg CT

sildenafil citrate 100 mg CT, single dose with water

DRUG

Viagra®

sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00904748 on ClinicalTrials.gov